Erivedge (vismodegib)

Erivedge is a capsule taken once-daily to treat adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or cannot be treated effectively with surgery or radiation. Erivedge works by blocking abnormal functioning of the Hedgehog cell signalling pathway. Abnormal activation of this pathway is responsible for tumour development in most basal cell carcinomas. Erivedge is approved in the United States, the European Union, Switzerland and many other countries across the world.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeCovid-19Pharma solutionsRoche careersMedia libraryAnnual Report 2023Privacy policyLegal statement